

A CME CONFERENCE JOINTLY SPONSORED BY:



Memorial Sloan-Kettering
Cancer Center



2ND INTERDISCIPLINARY CONFERENCE PROSTATE CANCER: PREDICTIVE MODELS FOR DECISION MAKING

An international multidisciplinary conference on finding new ways to improve decision making in prostate cancer

April 7-9, 2011

**Memorial Sloan-Kettering Cancer Center
New York, US**

Chair: Peter T. Scardino, MD, US

Co-Chair: Riccardo Valdagni, MD, PhD, IT

Honorary Chair: Louis J. Denis, MD, BE

Scientific Coordinator: Karim Touijer, MD, US



Registration open! Early rate before March 25, 2011

04/07/11

NEW YORK

Faculty

Gerald L. Andriole

Div. Urology, Washington University School of Medicine in St. Louis, Barnes Jewish Hospital, St. Louis, US

Peter Bach

Div. Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, US

Chris Bangma

Head, Dept. Urology, Erasmus Medical Centre, Rotterdam, NL

Ethan Basch

Div. Medicine, Memorial Sloan Kettering Cancer Center, New York, US

Joaquim Bellmunt

Section Chief, Solid Tumor Oncology (GU & GI) Medical Oncology Service, Hospital del Mar, Barcelona, ES

Anders Bjartell

Professor in Clinical Urology, Dept. Urology, Malmö and Lund University Hospitals, Lund University, Malmö, SE

Peter R. Carroll

Director, Clinical Services and Strategic Planning, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, US

Carlos Cordon Cardo

Vice-Chair and Professor of Pathology, Columbia University, New York, US

Brett W. Cox

Brachytherapy Service, Memorial Sloan Kettering Cancer Center, New York, US

David Dearnaley

Professor of Uro-Oncology, Dept. Radiotherapy, Institute of Cancer Research, London, UK

Louis Denis

Director, Oncology Centre Antwerp (OCA), Antwerp, BE

James A. Eastham

Chief, Urology Service and Florence and Theodore Baumritter/Enid Ancell Chair, Urologic Oncology, Memorial Sloan Kettering Cancer Center, New York, US

Mark Emberton

Divisional Clinical Director, Cancer Services, University College Hospitals, and Clinical Director, Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK

Jonathan I. Epstein

Professor, Dept. Pathology, Urology, & Oncology, The Reinhard Professor of Urologic Pathology, Johns Hopkins Medical Institutions, and Director, Surgical Pathology, Dept. Pathology, Johns Hopkins Hospital, Baltimore, US

Paul A. Fearn

NLM Informatics Research Fellow at University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, US

Christopher Foster

Professor of Cellular Pathology and Molecular Genetics, University of Liverpool, Liverpool, UK

Peter Hoskin

Professor and Honorary Consultant in Clinical Oncology, University College London, and Consultant in Clinical Oncology, Mount Vernon Cancer Centre, Northwood, UK

Hedvig Hricak

Chair, Dept. Radiology, Memorial Sloan Kettering Cancer Center, New York, US

Maha Hussain

Associate Director for Clinical Research, Dept. Internal Medicine, University of Michigan Health System, Ann Arbor, US

Andrew Jackson

Dept. Medical Physics, Memorial Sloan Kettering Cancer Center, New York, US

Michael W. Kattan

Chair, Dept. Quantitative Health Sciences, Cleveland Clinic, Cleveland, US

Eric Klein

Chair, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US

Laurence Klotz

Chief, Div. Urology, Sunnybrook Health Science Centre, Toronto, CA

Mark Litwin

Professor of Urology and Health Services, University of California, and Clark Urological Center, Ronald Reagan UCLA Medical Center, Los Angeles, US

Alvaro A. Martinez

Corporate Chairman, Radiation Oncology Dept., William Beaumont Hospitals, Royal Oak, US

Rodolfo Montironi

Institute of Pathological Anatomy and Histopathology, Marche Polytechnic University, United Hospitals, Le Torrette, IT

Francesco Montorsi

Head, Sexual Medicine Unit, Attending Urologist, Dept. Urology, Istituto Scientifico San Raffaele, Milan, IT

John P. Mulhall

Director, Male Sexual and Reproductive Medicine Program, Memorial Sloan Kettering Cancer Center, New York, US

Robert Nam

Clinical Epidemiology, Odette Cancer Research Program, Sunnybrook Health Science Centre, Toronto, CA

Simon Powell

Dept. Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, US

Andrea Pusic

Div. Plastic Surgery, Memorial Sloan Kettering Cancer Center, New York, US

Farhang Rabbani

Associate Professor, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, US

Tiziana Rancati

Prostate Program, Scientific Director's Office, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

Victor E. Reuter

Vice Chair, Dept. Pathology and Director, Immunohistochemistry Core Facility, Memorial Sloan Kettering Cancer Center, New York, US

Mack Roach III

Professor, Depts. Radiation Oncology & Urology, Chairman, Dept. Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, US

Fred Saad

Professor and Chief of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, CA

Martin G. Sanda

Director, Prostate Care Center, Div. Urology, Beth Israel Deaconess Medical Center, Boston, US

Jaspreet S. Sandhu

Dept. Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, US

Charles L. Sawyers

Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, US

Peter T. Scardino

Chief, Dept. Surgery, Memorial Sloan Kettering Cancer Center, New York, US

Howard I. Scher

Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, US

Matthew R. Smith

Associate Professor, Dept. Medicine, Harvard Medical School, Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, US

Andrew Stephenson

Head, Urologic Oncology, Cleveland Clinic's Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US

Cora N. Sternberg

Head, Dept. Medical Oncology, Ospedale San Camillo, Rome, IT

Steven Stone

V.P. of Cancer Genomics, Myriad Genetics Inc, Salt Lake City, US

Karim Touijer

Assistant Attending, Dept. Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, Assistant Professor of Urology, Weill Medical College, Cornell University, New York, US

Riccardo Valdagni

Director, Prostate Program, Scientific Director's Office, Director, Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

Hein Van Poppel

Chair, Dept. Urology, University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, BE

Andrew Vickers

Associate Attending Research Methodologist, Div. Health Outcomes, Dept. Epidemiology & Statistics, Memorial Sloan Kettering Cancer Center, New York, US

Anthony L. Zietman

Professor of Radiation Oncology, Dept. Radiation Oncology, Harvard Medical School, and Director, Radiation Oncology Residency Program, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Boston, US

Program

THURSDAY, APRIL 7TH

8:00 **Opening and welcome**
P.T. Scardino, US

8:05 **Making predictions throughout history**
R. Valdagni, IT

PREDICTIVE MODELS FROM BENCH TO BEDSIDE AND BACK TO BENCH

Chair: P.R. Carroll, US - R. Montironi, IT

8:20 **Data management for predictive tools**
P.A. Fearn, US

8:35 **Construction of predictive tools and measurements of their accuracy**
M.W. Kattan, US

8:50 **Imaging and outcomes prediction**
H. Hricak, US

9:05 **Molecular markers and outcome prediction**
C. Foster, UK

9:20 **Gene copy number analysis as a prognostic tool**
C.L. Sawyers, US

9:50 *Coffee break*

10:10 **Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach**
A. Vickers, US

10:25 **Genomic approaches to outcome prediction**
S. Stone, US

10:40 **Systems pathology and outcome predictive models**
C. Cordon Cardo, US

10:55 **Principles of biomarkers from discovery to qualification**
H.I. Scher, US

11:25 Panel discussion

DO MOLECULAR MARKERS IMPROVE PREDICTIVE MODELS?

Chair: P.R. Carroll, US - R. Montironi, IT

Panelists: C. Cordon Cardo, US - P.A. Fearn, US - C. Foster, UK
M.W. Kattan, US - C.L. Sawyers, US - H.I. Scher, US
S. Stone, US - A. Vickers, US

12:05 *Lunch*

PREDICTING DIAGNOSIS AND STAGE

Chair: A. Bjartel, SE - J.A. Eastham, US

1:10 **Predicting risk of cancer on biopsy**
R. Nam, CA

1:30 **Predicting pathological stage and change**
V.E. Reuter, US

1:50 **Predicting grade**
J.I. Epstein, US

PREDICTIVE MODELS IN LOW RISK PROSTATE CANCER

Chair: A. Bjartel, SE - M. Emberton, UK

2:25 **Predicting indolent and low risk prostate cancer**
C. Bangma, NL

2:45 **Predicting focal cancer**
M. Emberton, UK

3:05 **Utility of clinical and biochemical parameters in Active Surveillance as triggers for intervention**
L. Klotz, CA

3:25 Panel discussion

PREDICTIVE MODELS IN LOW RISK PROSTATE CANCER: LIMITATIONS AND FUTURE NEEDS

Chair: C. Bangma, NL - P.T. Scardino, US

Panelists: B.W. Cox, US - P.R. Carroll, US - M. Emberton, UK
L. Klotz, CA - A. Vickers, US - A.L. Zietman, US

FRIDAY, APRIL 8TH

MODELS TO PREDICT PROGNOSIS AFTER THERAPY IN LOCALIZED PROSTATE CANCER

Chair: S. Powell, US - H. Van Poppel, BE

8:00 **Predicting clinical and biochemical endpoints before surgery**
K. Touijer, US

8:15 **Predicting clinical and biochemical endpoints after surgery**
A. Stephenson, US

8:30 **Predicting clinical and biochemical endpoints before external radiotherapy**
B.W. Cox, US

8:50 **Predicting clinical and biochemical endpoints before external radiotherapy combined with hormonal therapy**
D. Dearnaley, UK

9:10 **Predicting clinical and biochemical endpoints before brachytherapy**
A.A. Martinez, US

9:30 Panel discussion

WHAT ARE THE LIMITATIONS OF CURRENT PREDICTIVE MODELS?

Chair: E. Kein, US - F. Montorsi, IT

Panelists: A. Bjartel, SE - D. Dearnaley, UK - M.W. Kattan, US
M. Roach III, US - F. Saad, CA - A. Stephenson, US
C.N. Sternberg, IT

10:00 *Coffee break*

MODELS TO PREDICT PROGNOSIS IN ADVANCED DISEASE

Chair: J. Bellmunt, ES - H.I. Scher, US

- 10:15 **Predicting life expectancy**
P. Bach, US
- 10:40 **Predicting response to hormonal therapy and survival in men with biochemical recurrence**
M.H. Hussain, US
- 11:05 **Role of Circulating Tumor Cells in predicting survival in men with castration resistant disease**
C.N. Sternberg, IT
- 11:30 Panel discussion
DO WE NEED BETTER PREDICTIVE MODELS IN ADVANCED PROSTATE CANCER?
Chair: M.R. Smith, US - C.N. Sternberg, IT
Panelists: J. Bellmunt, ES - J. Eastham, US - P. Hoskin, UK
M.H. Hussain, US - M.W. Kattan, US - M. Roach III, US
H.I. Scher, US

12:10 *Lunch*

QUALITY OF LIFE OUTCOME MEASUREMENT

Chair: D. Dearnaley, UK - E. Klein, US

- 1:10 **Documenting outcomes with patient reported questionnaires**
M. Litwin, US
- 1:30 **Comparing side effects with validated quality of life instruments**
M.G. Sanda, US
- 1:50 **Quality of life instruments and their role in cancer care**
A. Pusic, US
- 2:10 Panel discussion
ADVANTAGES AND LIMITATIONS OF CURRENT QUALITY OF LIFE INSTRUMENTS
Chair: L. Klotz, CA - F. Montorsi, IT
Panelists: E. Basch, US - P. Hoskin, UK - E. Klein, US - M. Litwin, US
A. Pusic, US - M.G. Sanda, US - A. Vickers, US

2:40 *Coffee break*

Three breakout sessions

MODELS TO PREDICT THERAPY INDUCED TOXICITIES

UROLOGY ROOM

Chair: J.A. Eastham, US - J.P. Mulhall, US

- 3:00 **Should surgeon specific factors be incorporated in prediction modeling?**
A. Vickers, US
- 3:25 **Predicting toxicity after surgery: incontinence**
J.S. Sandhu, US
- 3:50 **Predicting toxicity after surgery: erectile dysfunction**
F. Montorsi, IT

- 4:15 **Predicting toxicity after surgery: morbidity and complications**
F. Rabbani, US
- 4:40 **Urology group discussion**
How to design the next generation of predictive models in Urology?

RADIATION ONCOLOGY ROOM

Chair: A. Jackson, US - A.L. Zietman, US

- 3:00 **How the radiation oncologist and the radiation technique affect outcome**
P. Hoskin, UK
- 3:20 **Predicting toxicity after external radiotherapy: sexual and urinary dysfunction**
M. Roach III, US
- 3:40 **Predicting toxicity after external radiotherapy: gastro-intestinal dysfunction**
R. Valdagni, IT
- 4:00 **Predicting toxicity after brachytherapy**
A.A. Martinez, US
- 4:20 **Predicting radio-induced toxicity: the challenge of moving from qualitative events to quantitative scoring**
T. Rancati, IT
- 4:40 **Predicting toxicity after external radiotherapy: dosimetric issues**
J. Jackson, US
- 5:00 **Radiation Oncology group discussion**
How to design the next generation of predictive models in radiation oncology?

MEDICAL ONCOLOGY ROOM

Chair: M.H. Hussain, US - H.I. Scher, US

- 3:00 **Predicting toxicity after androgen deprivation: cardiovascular events**
M.R. Smith, US
- 3:25 **Predicting toxicity after androgen deprivation: skeletal adverse events**
F. Saad, CA
- 3:50 **Role of predictive biomarkers as a measure of individualized medicine**
M.H. Hussain, US
- 4:15 **Medical Oncology group discussion**
How to design the next generation of predictive models for advanced disease?

SATURDAY, APRIL 9TH

HIGHLIGHTS OF THE BREAKOUT SESSIONS

- 8:30 **Urology Room**
K. Touijer, US
- 8:45 **Radiation Oncology room**
B.W. Cox, US
- 9:00 **Medical Oncology room**
F. Saad, CA

POINT, COUNTERPOINT

Chair: L. Denis, BE - P.T. Scardino, US

- 9:30 Debate: **DO I NEED A NOMOGRAM TO MAKE GOOD DECISIONS?**

The answer is no

H. Van Poppel, BE

The answer is yes

M.W. Kattan, US

- 10:00 **PANEL DISCUSSION**

Chair: E. Klein, US - H.I. Scher, US

Panelists: C. Cordon Cardo, US - P. Hoskin, UK - R. Montironi, IT
V.E. Reuter, US - S. Stone, US - A. Vickers, US

- 10:30 *Coffee Break*

- 10:50 Debate: **CATEGORICAL STAGING VERSUS CONTINUOUS PREDICTION: HOW CAN WE INTEGRATE PREDICTIVE MODELS INTO THE STAGING SYSTEMS?**

Categorical staging works!

P.R. Carroll, US

Categorical staging vs prediction models: what is the evidence?

A. Vickers, US

- 11:20 **PANEL DISCUSSION**

Chair: K. Touijer, US - H. Van Poppel, BE

Panelists: P. Bach, US - P.R. Carroll, US - M.W. Kattan, US
F. Montorsi, IT - M. Roach III, US - M.R. Smith, US
A.L. Zietman, US

- 11:50 Debate: **CLINICAL TRIALS DESIGN**

Predictive models are a better way to stratify patients for clinical trials

J.A. Eastham, US

Standard stratification is adequate for clinical trials

G.L. Andriole, US

- 12:20 **PANEL DISCUSSION**

Chair: C.N. Sternberg, IT - A.L. Zietman, US

Panelists: A. Bjartell, SE - D. Dearnaley, UK - M.H. Hussain, US
M. Roach III, US - M.R. Smith, US - A. Vickers, US

- 12:50 **Closing Remarks**

General information

For more information, please contact:

Office of Continuing Medical Education
Memorial Sloan-Kettering Cancer Center
New York (US)
Telephone: (646) 227-2025
Facsimile: (212) 557-0773
E-mail: brodheap@mskcc.org

Prostate Cancer Programme
European School of Oncology
Milan (Italy)
Telephone: +39 02 85464527
Facsimile: +39 02 85464545
E-mail: prostate@eso.net

CONFERENCE LOCATION

Memorial Sloan-Kettering Cancer Center
Rockefeller Research Laboratories Conference Center
430 East 67th Street, between First and York Avenues, 10065 New York, US

INFORMATION AVAILABLE AT
www.eso.net and www.mskcc.org/cme

ONLINE REGISTRATION

Registration may be carried out online at www.mskcc.org/cme or by returning the enclosed registration form.

Important registration deadlines are as follows:

Early registration: before MARCH 25, 2011

Late registration: MARCH 25 through APRIL 7, 2011

Cancellation deadline: MARCH 25, 2011

The number of seats at the conference venue is limited and therefore, early registration is strongly recommended. Onsite registration will be accommodated according to availability but no guarantees can be made.

The registration fee covers admission to the conference, a copy of the program book, coffee and lunch throughout the conference as indicated in the program.

CONFIRMATION OF REGISTRATION

Registration will be confirmed by a message sent to the registrant's indicated email address.

CANCELLATION OF REGISTRATION

Written notice of cancellation must be received no later than **March 25, 2011**. Refunds are subject to a \$65 administrative charge and will be processed after the conference. For more information, please contact the Memorial Sloan-Kettering Cancer Center, CME Office at 646-227-2025, Fax: +1-212-557-0773, Address: 633 Third Avenue, 12th FL, New York, NY 10017 or via e-mail brodheap@mskcc.org: Replacement is allowed but will be accepted upon written communication only before March 20, 2011.

EVALUATION

A course evaluation form will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Memorial Sloan-Kettering Cancer Center and the European School of Oncology. Memorial Sloan-Kettering Cancer Center is accredited by the ACCME to provide continuing medical education for physicians. The European School of Oncology will apply for ACOE accreditation.

AMA CME CREDIT DESIGNATION STATEMENT

Memorial Sloan-Kettering Cancer Center designates this educational activity for a maximum of **18.0 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT

No commercial support has been provided for this CME activity. Memorial Sloan-Kettering Cancer Center (MSKCC) does not accept commercial support for its CME Program.

FACULTY DISCLOSURE

Memorial Sloan-Kettering Cancer Center (MSKCC) relies upon faculty participants in its CME Program to provide educational information that is objective and as free from bias as possible. In accordance with nationally accepted guidelines, faculty members are asked to indicate any commercial relationship that might be perceived as a real or apparent conflict of interest.

HOTEL INFORMATION FOR PARTICIPANTS

Please consult the website below to access information on hotels in the vicinity of Memorial Sloan-Kettering Cancer Center: **www.mskcc.org/accommodations**

Also, for any specific requests please contact the Office of Continuing Medical Education at MSKCC and we will make every effort to assist you.

CERTIFICATES

All participants will be issued with an ESO-MSKCC certificate of attendance at the end of the Conference.

OFFICIAL LANGUAGE

The official language of the conference is English. No simultaneous translation will be provided.

BADGE

Your name badge is the only official evidence of registration and should be worn at all times during the Conference.

INSURANCE

The organizers bear no responsibility for untoward events in connection between with, before, during and after the conference. Participants are strongly advised to take their own personal and travel insurance coverage.

IMPORTANT DEADLINES

Early registration: before MARCH 25, 2011

Registration: MARCH 25 through APRIL 7, 2011

Cancellation deadline: MARCH 25, 2011

Replacement deadline: MARCH 25, 2011

